How it works:
Thalidomide inhibits the formation of new blood vessels (anti-angiogenic effect), reduces tumour necrosis factor-alpha (TNF-α), and modulates immune response by affecting T cells and cytokine release, making it effective in both cancer and inflammatory conditions.
Recommended for:
Multiple myeloma (as part of combination therapy)
Leprosy-related erythema nodosum (ENL)
Off-label use in Crohn’s disease, HIV ulcers, autoimmune diseases (physician-directed)
Requires strict medical supervision and pregnancy prevention for women of childbearing potential
Multiple myeloma (in combination with other agents)
Erythema nodosum leprosum (ENL)
Experimental use in autoimmune and inflammatory conditions (off-label)
THALIX-100 should be taken orally. The dosage is determined by a physician based on diagnosis, body weight, and treatment protocol. Tablets should be swallowed whole with water, preferably in the evening to reduce sedative effects.
Pregnancy (high teratogenic risk)
Intent to conceive
Known allergy to thalidomide
Severe peripheral neuropathy
Paediatric use
Lactose intolerance or glucose-galactose malabsorption
Drowsiness, dizziness
Peripheral neuropathy
Constipation, skin rash
Thromboembolic events
Menstrual irregularities
Anaemia, thrombocytopenia
Severe birth defects (if taken during pregnancy)
